SCHEDULE 13G/A: Slate Path Capital LP and David Greenspan Amend Beneficial Ownership in Cue Biopharma, Holding 1.4% Stake

Slate Path Capital LP and David Greenspan have filed an amended Schedule 13G, disclosing a beneficial ownership of 1.4% in Cue Biopharma, Inc., primarily through shares issuable upon warrant exercise.

Summary

• Slate Path Capital LP and David Greenspan, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Cue Biopharma, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 918,836 shares of Cue Biopharma, Inc. common stock.
• This ownership represents 1.4% of the company's outstanding common stock.
• The reported shares include 918,836 shares of common stock issuable upon the exercise of warrants directly held by Slate Path Master Fund LP and SPB Master Fund LP (the "Slate Path Funds").
• The percentage of class is calculated based on 63,350,327 shares of Common Stock outstanding as of November 12, 2024, as reported in Cue Biopharma's Form 10-Q for the quarter ended September 30, 2024.
• Slate Path Capital LP is a Delaware limited partnership and the investment manager for the Slate Path Funds.
• David Greenspan is the managing partner of Jades GP, LLC, the general partner of Slate Path Capital LP, and a citizen of the United States.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cue Biopharma, Inc.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing (Schedule 13G/A) disclosing beneficial ownership. It contains no forward-looking statements, financial performance data, or strategic updates that would indicate a positive or negative sentiment. It is purely informational and neutral.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor, Slate Path Capital LP, and its managing partner, David Greenspan, in Cue Biopharma, Inc., a biotechnology company. Such filings provide transparency regarding significant holdings but do not typically reflect broader industry trends or competitive positioning beyond the investor's interest in the company.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership stake held by Slate Path Capital LP and David Greenspan, confirming their continued investment in the company.

Key Dates

Keywords

Cue Biopharma, Slate Path Capital LP, David Greenspan, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment Management, Institutional Investor